文献速递脑血管病认知障碍与痴呆

脑淀粉样蛋白沉积是否影响卒中后长期认知结局:IDEA3研究

Do Amyloid Cerebral Deposits Influence the Long-Term Poststroke Cognitive Outcome?: The IDEA3 Study.
PubMed 文献 · Stroke · 2024-12-09

IDEA3队列在亚眠大学医院纳入91例卒中患者,基线florbetapir PET阳性14例,每年进行临床与认知评估共5年。PET阳性者新发痴呆(OR 9.6,95%CI 2.5-36.9,P=0.001)和新发认知障碍(OR 10,95%CI 1.9-52.3,P=0.003)风险更高,末次随访时痴呆(OR 6,95%CI 1.76-20.5,P=0.002)和卒中后认知障碍(OR 6.25,95%CI 1.77-22,P=0.002)风险亦升高;最终改良Rankin量表评分无显著差异(P=0.3)。

要点

  • 卒中后基线淀粉样PET阳性者5年内新发痴呆风险升高(OR 9.6,95%CI 2.5-36.9,P=0.001)。
  • PET阳性者新发认知障碍风险亦升高(OR 10,95%CI 1.9-52.3,P=0.003)。
  • 末次随访时PET阳性与痴呆(OR 6,95%CI 1.76-20.5,P=0.002)和卒中后认知障碍(OR 6.25,95%CI 1.77-22,P=0.002)风险升高相关。

核心结论

  • 淀粉样蛋白沉积对卒中结局有重大影响,卒中后认知障碍患者需进行全面病因学检查。

研究设计与样本

  • 纵向研究,在亚眠大学医院纳入91例卒中患者(缺血性卒中89%,出血性卒中11%),基线有florbetapir PET数据(阳性n=14)。
  • 纳入时间2014年10月至2019年10月,末次随访2018年10月至2023年2月,PET扫描后每年进行综合临床与认知评估共5年。
  • 主要结局为新发痴呆,次要结局为新发认知障碍、认知障碍总患病率和改良Rankin量表评分。

主要发现

  • 生存分析(平均卒中后随访80.4±27个月)显示PET阳性患者新发痴呆发生率更高(OR 9.6,95%CI 2.5-36.9,P=0.001)。
  • PET阳性患者新发认知障碍发生率更高(OR 10,95%CI 1.9-52.3,P=0.003)。
  • Cox回归分析显示,调整年龄、教育程度、卒中前改良Rankin量表评分和认知障碍、卒中类型及PET状态×卒中类型交互作用后,淀粉样状态与痴呆(P=0.001)和认知障碍(P=0.007)发生率的关联仍显著。
  • 末次随访时全研究人群(n=91)中,PET阳性与痴呆风险升高(OR 6,95%CI 1.76-20.5,P=0.002)和卒中后认知障碍风险升高(OR 6.25,95%CI 1.77-22,P=0.002)相关。
  • 最终改良Rankin量表评分按PET状态无显著差异(P=0.3)。

临床怎么用

  • 作者认为淀粉样蛋白沉积对卒中结局有重大影响,并强调卒中后认知障碍患者需进行全面病因学检查。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although the presence of amyloid deposits is associated with a more severe cognitive status in patients with stroke at baseline, its influence on the subsequent cognitive outcome has not been extensively assessed. The primary objective of the present study of the IDEA3 (Imagerie des dépôts amyloïdes cérébraux par florbetapir AV-45 et diagnostic des déficits cognitifs et démence post Accident Vasculaire Cérébral) cohort was to determine the influence of amyloid positron emission tomography (PET) status on the 5-year cognitive outcome. METHODS: This longitudinal study performed in Amiens University Hospital (inclusions: October 2014 to October 2019; last visits: October 2018 to February 2023) has included 91 patients with stroke (ischemic stroke, 89%; hemorrhagic stroke, 11%) with florbetapir PET data at baseline (positive, n=14). Patients underwent annually comprehensive clinical and cognitive assessments for 5 years after the PET scan. The primary outcome was incident dementia; secondary outcomes were incident cognitive impairment, total prevalence of cognitive impairment, and modified Rankin Scale score. RESULTS: A survival analysis (mean poststroke follow-up, 80.4±27 months) showed that the incidence of incident dementia was higher in the PET-positive patients (odds ratio, 9.6 [95% CI, 2.5-36.9]; P=0.001), as was the incidence of incident cognitive impairment (odds ratio, 10 [95% CI, 1.9-52.3]; P=0.003). A Cox regression analysis showed that the association between amyloid status and the incidences of dementia (P=0.001) and cognitive impairment (P=0.007) was still significant after adjustment for age, education, prestroke modified Rankin Scale score and cognitive impairment, stroke type, and the PET status×stroke type interaction. Considering the overall prevalence at the last follow-up in the whole study population (n=91 patients), PET positivity was associated with an elevated risk of dementia (odds ratio, 6 [95% CI, 1.76-20.5]; P=0.002) and poststroke cognitive impairment (odds ratio, 6.25 [95% CI, 1.77-22]; P=0.002). The final modified Rankin Scale score did not differ (P=0.3) according to PET status. CONCLUSIONS: Our results demonstrate the major impact of amyloid deposition on the stroke outcome and emphasized the need for comprehensive etiologic workup in patients with poststroke cognitive impairment. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02813434.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Godefroy O, Trinchard N, Marchal E, et al. Do Amyloid Cerebral Deposits Influence the Long-Term Poststroke Cognitive Outcome?: The IDEA3 Study. Stroke. 2024. PMID: 39648884. doi:10.1161/STROKEAHA.124.049147

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。